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Members of the Burkholderia cepacia complex (Bcc),
found in many environments, are associated with clinical
infections. Examining diverse species and strains from dif-
ferent environments with multilocus sequence typing, we
identified >20% of 381 clinical isolates as indistinguishable
from those in the environment. This finding links the natural
environment with the emergence of many Bcc infections.
T
he Burkholderia cepacia complex (Bcc) is a group of
closely related gram-negative bacteria comprising at
least 9 species (1). They are routinely isolated from the
natural environment, where they can have a range of ben-
eficial properties (2). However, these bacteria can also fre-
quently cause fatal infections in vulnerable humans, such
as those who have cystic fibrosis (CF). Because Bcc bac-
teria are not normally carried as commensal organisms, the
main sources of infection are considered to be patient-to-
patient spread (3,4); hospital settings, including medical
devices and contaminated disinfectants; and the environ-
ment (5,6). Therefore, although Bcc species may have an
important environmental role in agriculture and biotech-
nology industries, their use also represents a potential clin-
ical risk to susceptible members of the community (7,8).
All species of Bcc can be isolated from the environment in
differing degrees (2). Similarly, all current Bcc species
have been cultured from CF patient sputum (2). Infection
control measures have been implemented to reduce
patient-to-patient transmission; although effective, these
measures have not prevented the emergence of new infec-
tion. Thus, the environment could be acting as a constant
nonpatient reservoir for infectious Bcc pathogens.
Previous studies have reported the possibility of
humans acquiring Bcc directly from natural environments
(9,10). The most recent of these studies reported evidence
that a B. cenocepacia strain, isolated from soil, was indis-
tinguishable by several typing methods (pulsed-field gel
electrophoresis [PFGE] genomic fingerprinting and repet-
itive extragenic palindromic [rep]–PCR) from isolates of
the problematic CF lineage PHDC (10). 
The Study
To evaluate how widespread the emergence of envi-
ronmental isolates as causes of clinical infections may be,
we used a highly discriminatory and transportable typing
method to study isolates from several large bacterial cul-
ture collections. Multilocus sequence typing (MLST) is a
relatively new technique based upon unambiguous
sequence analysis of several housekeeping genes. Unlike
previous methods for Bcc strain typing (10), MLST is not
based on banding patterns but instead relies on the robust
comparison of DNA sequence information. This process
facilitates both the identification and matching of identical
clones as well as their evolutionary comparison to closely
related strains.
Using a recently validated MLST scheme (11), we
analyzed a collection of 381 clinical isolates of all 9 cur-
rently reported Bcc species, from 28 countries. A total of
187 distinct sequence types (STs) were identified from
clinical isolates within this collection and compared with
233 environmental Bcc isolates (113 STs). We found that
81 clinical isolates (encompassing15 STs) were identical
by MLST to a wide range of environmental isolates. This
figure represents 21.5% of the clinical isolates examined
(for clarity, a subset are shown in the Table; [12]).
The resolution of strain identification offered by
MLST is such that different isolates sharing the same ST
(genotypically indistinguishable at all 7 loci) are defined as
clones of the same strain (e.g., for a group of isolates with-
in this collection, we have further validated this identity by
cloning and sequencing up to 10 random fragments of
DNA). The 15 STs identified from environmental and clin-
ical sources belonged to 6 different Bcc species (Table): B.
cepacia (4 STs), B. multivorans (2 STs), B. cenocepacia (3
STs), B. stabilis (2 STs), B. vietnamiensis (2 STs), and B.
ambifaria (2 STs). Three B. cenocepacia STs also
belonged to 2 different recA lineages defined within this
species: IIIA (1 ST) and IIIB (2 STs).
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STs occurring in both clinical and environmental nich-
es were found in 6 of the 9 formally described Bcc; the
greatest degree of overlap occurred in B. cepacia and B.
stabilis (Figure). The proportion of STs not shared between
clinical and environmental isolates varied for each Bcc
species we examined. This finding may reflect the few
clinical or environmental isolates for that species or high
genetic diversity; a larger sample size is needed to find
identical matches. Species dominated by clinical STs
(>83% of STs) were B. multivorans, B. cenocepacia recA
lineage IIIA, and B. dolosa. Those species containing
mainly environmental STs (>80%) were B. ambifaria, B.
anthina, and B. pyrrocinia (Figure). Although this distribu-
tion agrees with findings of previous studies (2), it also
reflects the distribution of isolates within the collections
from which isolates were obtained.
Several ST matches between clinical and environmen-
tal isolates were of particular interest. MLST ST-10 was
shared by B. cepacia J1050, a human isolate cultured in the
United States (Cleveland, Ohio) and the type strain for B.
cepacia ATCC 25416, isolated from an onion. This evi-
dence of clonality augments the clonal relationship report-
ed earlier (9) between ATCC 25416 and a UK isolate from
a CF patient. The B. multivorans IST455 isolated from a CF
patient’s sputum in Portugal, as reported in a previous study
(13)  had the same sequence type (ST-375) as R-20526,
which was isolated from the River Schelde in Belgium.
B. cenocepacia recA lineage IIIA isolates with ST-32
(Table) were from 4 independent sources: POPR8 (isolat-
ed from a radish in Mexico), BCC1118 (isolated from a
UK non-CF patient infection), R-16597 (isolated from a
CF patient in Belgium), and 5–457 (isolated from a CF
patient in the Czech Republic). ST-32 appears to be a glob-
ally distributed, predominantly clinical strain (A. Baldwin,
unpub. data). The B. cenocepacia recA lineage IIIB iso-
lates identified as ST-122 (Table) include the PHDC
strains, predominant in US CF patients (AU1054) and pre-
viously found in US soil (HI-2424) (10), and CEP0497,
which was obtained from a leg wound in a non-CF patient
in Canada. Together with a recent report of PHDC strains
identified in Europe (14), the Canadian isolate in our study
adds further weight to the identification of this ST as a
globally distributed strain.
MLST analysis of B. stabilis corroborated the high
degree of clonality observed by PFGE fingerprint analysis
in the original description of this species (15). However,
MLST was further able to distinguish 8 STs among the 26
isolates examined, which indicates that MLST may be a
more effective method than PFGE for epidemiologic
analysis of B. stabilis. This increased resolution adds to the
observation that 2 B. stabilis STs are globally distributed
and isolated from clinical samples and an array of different
niches, including domestic products, medical solutions,
industrial process contaminants, and hospital devices.
In summary, >20% of the clinical isolates we exam-
ined were indistinguishable by MLST from isolates from
environmental sources. This finding suggests that conser-
vation of intrinsic determinants necessary to thrive in envi-
ronmental niches may confer an ability to colonize
susceptible humans. Further work is urgently required to
more extensively investigate the emergence of pathogenic
members of the Bcc in the natural environment and the risk
for infection this may represent.
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